These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 24935355)

  • 1. Serum microRNA-210 as a predictive biomarker for treatment response and prognosis in patients with hepatocellular carcinoma undergoing transarterial chemoembolization.
    Zhan M; Li Y; Hu B; He X; Huang J; Zhao Y; Fu S; Lu L
    J Vasc Interv Radiol; 2014 Aug; 25(8):1279-1287.e1. PubMed ID: 24935355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transcatheter arterial chemoembolization for advanced hepatocellular carcinoma with portal vein invasion: safety, efficacy, and prognostic factors.
    Chern MC; Chuang VP; Liang CT; Lin ZH; Kuo TM
    J Vasc Interv Radiol; 2014 Jan; 25(1):32-40. PubMed ID: 24290099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transcatheter arterial chemoembolization with doxorubicin-eluting superabsorbent polymer microspheres in the treatment of hepatocellular carcinoma: midterm follow-up.
    Dekervel J; van Malenstein H; Vandecaveye V; Nevens F; van Pelt J; Heye S; Laleman W; Van Steenbergen W; Vaninbroukx J; Verslype C; Maleux G
    J Vasc Interv Radiol; 2014 Feb; 25(2):248-55.e1. PubMed ID: 24295569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modified cisplatin-based transcatheter arterial chemoembolization for large hepatocellular carcinoma: multivariate analysis of predictive factors for tumor response and survival in a 163-patient cohort.
    Yoon HM; Kim JH; Kim EJ; Gwon DI; Ko GY; Ko HK
    J Vasc Interv Radiol; 2013 Nov; 24(11):1639-46. PubMed ID: 23962438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum microRNA-1 and microRNA-122 are prognostic markers in patients with hepatocellular carcinoma.
    Köberle V; Kronenberger B; Pleli T; Trojan J; Imelmann E; Peveling-Oberhag J; Welker MW; Elhendawy M; Zeuzem S; Piiper A; Waidmann O
    Eur J Cancer; 2013 Nov; 49(16):3442-9. PubMed ID: 23810247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Downstaging disease in patients with hepatocellular carcinoma outside of Milan criteria: strategies using drug-eluting bead chemoembolization.
    Green TJ; Rochon PJ; Chang S; Ray CE; Winston H; Ruef R; Kreidler SM; Glueck DH; Shulman BC; Brown AC; Durham J
    J Vasc Interv Radiol; 2013 Nov; 24(11):1613-22. PubMed ID: 24060436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Degradable starch microspheres versus ethiodol and doxorubicin in transarterial chemoembolization of hepatocellular carcinoma.
    Niessen C; Unterpaintner E; Goessmann H; Schlitt HJ; Mueller-Schilling M; Wohlgemuth WA; Stroszczynski C; Wiggermann P
    J Vasc Interv Radiol; 2014 Feb; 25(2):240-7. PubMed ID: 24291001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transarterial Chemoembolization versus Radiofrequency Ablation for Recurrent Hepatocellular Carcinoma after Resection within Barcelona Clinic Liver Cancer Stage 0/A: A Retrospective Comparative Study.
    Chen R; Gan Y; Ge N; Chen Y; Wang Y; Zhang B; Wang Y; Ye S; Ren Z
    J Vasc Interv Radiol; 2016 Dec; 27(12):1829-1836. PubMed ID: 27553917
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Response Evaluation Criteria in Solid Tumors (RECIST) criteria are superior to European Association for Study of the Liver (EASL) criteria at 1 month follow-up for predicting long-term survival in patients treated with transarterial chemoembolization before liver transplantation for hepatocellular cancer.
    Shuster A; Huynh TJ; Rajan DK; Marquez MA; Grant DR; Huynh DC; Jaskolka JD
    J Vasc Interv Radiol; 2013 Jun; 24(6):805-12. PubMed ID: 23562641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High expression of serum miR-17-5p associated with poor prognosis in patients with hepatocellular carcinoma.
    Zheng J; Dong P; Gao S; Wang N; Yu F
    Hepatogastroenterology; 2013 May; 60(123):549-52. PubMed ID: 23108086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemoembolization for hepatocellular carcinoma: multivariate analysis of predicting factors for tumor response and survival in a 362-patient cohort.
    Hu HT; Kim JH; Lee LS; Kim KA; Ko GY; Yoon HK; Sung KB; Gwon DI; Shin JH; Song HY
    J Vasc Interv Radiol; 2011 Jul; 22(7):917-23. PubMed ID: 21571545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Modified Model for Assessment for Retreatment with Transarterial Chemoembolization in Chinese Hepatocellular Carcinoma Patients.
    Chen L; Ni CF; Chen SX; Cao JM; Zhu HD; Guo JH; Zhu GY; Zhong BY; Ding W; He SC; Deng G; Teng GJ
    J Vasc Interv Radiol; 2016 Sep; 27(9):1288-1297. PubMed ID: 27013402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of alpha-fetoprotein status in the outcome of hepatocellular carcinoma after treatment of transarterial chemoembolization.
    Wang Y; Chen Y; Ge N; Zhang L; Xie X; Zhang J; Chen R; Wang Y; Zhang B; Xia J; Gan Y; Ren Z; Ye S
    Ann Surg Oncol; 2012 Oct; 19(11):3540-6. PubMed ID: 22532305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inflammatory markers are associated with outcome in patients with unresectable hepatocellular carcinoma undergoing transarterial chemoembolization.
    McNally ME; Martinez A; Khabiri H; Guy G; Michaels AJ; Hanje J; Kirkpatrick R; Bloomston M; Schmidt CR
    Ann Surg Oncol; 2013 Mar; 20(3):923-8. PubMed ID: 22965570
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transarterial chemoembolization with additional cisplatin infusion for hepatocellular carcinoma invading the hepatic vein.
    Kim HC; Lee JH; Chung JW; Kang B; Yoon JH; Kim YJ; Lee HS; Jae HJ; Park JH
    J Vasc Interv Radiol; 2013 Feb; 24(2):274-83. PubMed ID: 23369561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of doxorubicin drug-eluting bead transarterial chemoembolization in patients with advanced hepatocellular carcinoma.
    Prajapati HJ; Dhanasekaran R; El-Rayes BF; Kauh JS; Maithel SK; Chen Z; Kim HS
    J Vasc Interv Radiol; 2013 Mar; 24(3):307-15. PubMed ID: 23375519
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of the Interval between Transarterial Chemoembolization Sessions on Survival in Patients with Unresectable Hepatocellular Carcinoma.
    Kim HD; An J; Kim JH; Gwon DI; Shin JH; Ko GY; Yoon HK; Sung KB; Kim KM; Lee HC
    J Vasc Interv Radiol; 2016 Apr; 27(4):504-13. PubMed ID: 26896049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of chemoembolization for recurrent HCC after curative ablation therapy.
    Okabe N; Morimoto M; Kondo M; Moriya S; Numata K; Maeda S; Tanaka K
    Hepatogastroenterology; 2013 May; 60(123):395-99. PubMed ID: 23108088
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of characteristics and transarterial chemoembolization outcomes in patients with unresectable hepatocellular carcinoma and different viral etiologies.
    Chen BB; Shih IL; Wu CH; Hsu C; Chen CH; Shih TT; Liu KL; Liang PC
    J Vasc Interv Radiol; 2014 Mar; 25(3):371-8. PubMed ID: 24468045
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Expression of serum microRNAs (miR-222, miR-181, miR-216) in human hepatocellular carcinoma and its clinical significance].
    Zhan MX; Li Y; Hu BS; Shao PJ; Meng QW; He X; Huang JW; Lu LG
    Zhonghua Yi Xue Za Zhi; 2013 Jun; 93(23):1830-2. PubMed ID: 24124720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.